Stock LPTX LEAP THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-20 EDT 		5-day change 1st Jan Change
1.96 USD +1.03% Intraday chart for Leap Therapeutics, Inc. -10.91% -52.71%
05-14 HC Wainwright Adjusts Price Target on Leap Therapeutics to $5.50 From $7, Maintains Buy Rating MT
05-13 Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
HC Wainwright Adjusts Price Target on Leap Therapeutics to $5.50 From $7, Maintains Buy Rating
MT
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Leap Therapeutics, Inc. announced that it has received $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP
CI
Leap Therapeutics Announces $40 Million Private Placement
PR
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP
CI
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating
MT
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration
MT
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Leap Therapeutics, Inc. - Special Call
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium
CI
Transcript : Leap Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
PR
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients
CI
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
AQ
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
PR
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating
MT
Leap Therapeutics Reports Third Quarter 2023 Financial Results
PR
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LPTX Stock
  4. News Leap Therapeutics, Inc.